Investigating the Anabolic Response to Resistance Exercise After Critical Illness (ARTIST-2)

Sponsor
Karolinska University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05261984
Collaborator
(none)
60
1
2
11.8
5.1

Study Details

Study Description

Brief Summary

ICU survivors often suffer from long-term functional disability. An attenuated response to physical exercise in skeletal muscle after critical illness may contribute to persisting weakness.

The aim of this study is to investigate the effects of resistance exercise on muscle protein synthesis in former ICU patients. The investigators hypothesize that study subjects recovering from critical illness have an impaired anabolic response to resistance exercise after ICU stay as compared to non-critically ill controls.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Resistance exercise
  • Dietary Supplement: Oral protein supplementation
N/A

Detailed Description

Background

The debilitating impact of critical illness has been recognized for several decades. Disability related to intensive care is now described as a syndrome called ICU-acquired weakness (ICUAW). ICUAW affects up to 70% of ICU patients and is most common with higher illness severity. Patients that develop ICUAW require longer hospitalization and have a higher risk of death. Weakness may persists for several years in ICU survivors. It has significant long-term consequences, and is associated with increased health care costs, delayed return to work, and overall poor quality of life.

Muscle atrophy is a major contributor to ICUAW. Critical illness is associated with a rapid loss of skeletal muscle, induced by catabolic signals from proinflammatory cytokines and hormones. The ability to regain lost muscle mass during convalescence may also be impaired. In a small observational study, muscle atrophy resolved only in a minority of ICU survivors at six months after ICU discharge.

Studies in exercise physiology have demonstrated that resistance training and amino acid ingestion have synergistic effects on muscle protein synthesis in healthy subjects. It is therefore an appealing therapy to reconstitute muscle mass after critical illness. Despite several clinical trials, there is equipoise regarding the efficacy of exercise in improving physical function in-ICU after ICU discharge. These mixed signals are unsurprising given the heterogeneous causes of ICUAW.

Only a few studies in this field have examined muscle architecture or cellular signaling in response to training. However, the gold standard in determining the anabolic response to exercise is to directly measure the effects on protein synthesis and breakdown. There is still no published research using this methodology to assess the effects of exercise interventions in former ICU patients. To understand the role of physical exercise in regaining lost muscle mass, the investigators plan to investigate the anabolic effects to resistance training after critical illness.

Aim and hypothesis

The aim of this study is to determine the anabolic response to resistance exercise after critical illness. The investigators hypothesize that study subjects recovering from critical illness have an impaired anabolic response to resistance exercise after ICU stay as compared to non-critically ill controls.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Investigating the Anabolic Response to Resistance Exercise After Critical Illness: The ARTIST-2 Non-Randomized Controlled Trial
Actual Study Start Date :
Mar 8, 2022
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Former ICU patients

Research subjects with a prior history of ICU treatment within six months.

Procedure: Resistance exercise
Weighted knee extensions in four sets targeting 8-12 repetitions to failure.

Dietary Supplement: Oral protein supplementation
24 grams of hydrolyzed whey protein.

Active Comparator: Age- and sex-matched control group

Research subjects without a prior history of ICU treatment within the last 30 years, age- and sex-matched in a 1:2 ratio to the experimental arm.

Procedure: Resistance exercise
Weighted knee extensions in four sets targeting 8-12 repetitions to failure.

Dietary Supplement: Oral protein supplementation
24 grams of hydrolyzed whey protein.

Outcome Measures

Primary Outcome Measures

  1. Muscle protein fractional synthetic rate [150 minutes post-exercise.]

    The difference between the experimental and active comparator group in muscle protein fractional synthetic rate.

Secondary Outcome Measures

  1. Gene expression [150 minutes post-exercise.]

    The difference between the experimental and active comparator group in gene expression (mRNA) in skeletal muscle, assessed by RNA sequencing.

  2. Signaling pathways [150 minutes post-exercise.]

    The difference between the experimental and active comparator group in the activity of major anabolic/catabolic signalining pathways in skeletal muscle, assessed by western blot.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult (≥18 years) previously admitted to an ICU at Karolinska University Hospital for ≥3 days and discharged alive from hospital

OR

  • Adult (≥18 years) without a history of ICU admission within the last 30 years
Exclusion Criteria:
  1. Not able to provide informed consent

  2. 6 months since ICU discharge*

  3. Systemic anticoagulation with LMWH/UFH/DOAC in therapeutic dose range for deep vein thrombosis or pulmonary embolism, or dual antiplatelet therapy

  4. Clinically significant inherited or acquired disorder of hemostasis

  5. Lower-limb amputee

  6. Lower-limb atherosclerotic disease with critical ischemia.

  7. Recent fracture in lower limbs or significant osteoarthritis limiting movement in knee or hip joint

  8. Metastatic cancer or active hematological malignancy

  9. Inherited disorder of amino acid metabolism.

  10. Chronic muscle, neuromuscular or neurologic disease with prior documentation of clinically significant lower-limb involvement

  11. Pregnancy

  12. Single organ failure not requiring invasive mechanical ventilation during ICU stay*

Exclusion criteria marked with asterisk only apply to former ICU patients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinska University Hospital Huddinge Stockholm Sweden 14186

Sponsors and Collaborators

  • Karolinska University Hospital

Investigators

  • Principal Investigator: Martin Sundström Rehal, MD PhD, Karolinska University Hospital
  • Study Chair: Olav Rooyackers, PhD, Karolinska University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Martin Sundstrom Rehal, Principal Investigator, Karolinska University Hospital
ClinicalTrials.gov Identifier:
NCT05261984
Other Study ID Numbers:
  • K 2022-1113
First Posted:
Mar 2, 2022
Last Update Posted:
Jun 3, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Martin Sundstrom Rehal, Principal Investigator, Karolinska University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 3, 2022